Agilon Health Inc(AGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 6:01 PM ET (Korea 10/29 07:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -15.2 | Insider Own | 30.23% | Shs Outstand | 16.8M | Perf Week | 0.01% |
| Market Cap | 1.53B | Forward P/E | 52.67 | EPS next Y | 174.27% | Insider Trans | - | Shs Float | 11.7M | Perf Month | 16.44% |
| Enterprise Value | 1.30B | PEG | - | EPS next Q | -1.23 | Inst Own | 72.51% | Short Float | 7.67% | Perf Quarter | -5.94% |
| Income | -0.25B | P/S | 0.26 | EPS this Y | 90.51% | Inst Trans | 5.96% | Short Ratio | 3.47 | Perf Half Y | 226.28% |
| Sales | 5.92B | P/B | 6.71 | EPS next 5Y | - | ROA | -15.21% | Short Interest | 0.90M | Perf YTD | 428.53% |
| Book/sh | 13.56 | P/C | 5.94 | EPS past 3/5Y | -55.37% -36.6% | ROE | -78.94% | 52W High | -31.6% ($133.04) | Perf Year | 298.47% |
| Cash/sh | 15.32 | P/FCF | - | Sales past 3/5Y | 35.43% 37.24% | ROIC | -102.1% | 52W Low | 1116.58% ($7.48) | Perf 3Y | -79.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.86% | Gross Margin | -0.24% | Volatility(W/M) | 5.36% 5.19% | Perf 5Y | -84.94% |
| Dividend TTM | - | EV/Sales | 0.22 | Sales Y/Y TTM | 0.32% | Oper. Margin | -4.29% | ATR (14) | 4.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.08 | EPS Q/Q | 116.55% | Profit Margin | -4.24% | RSI (14) | 56.97 | Recom | 2.53 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.08 | Sales Q/Q | 7.15% | SMA20 | 4.43% ($87.14) | Beta | 3.13 | Target Price | $115.83 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/11/4 | SMA50 | 3.2% ($88.18) | Rel Volume | 0.89 | Prev Close | $90.65 |
| Employees | 856 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | 622.22% 3.03% | SMA200 | 41.36% ($64.37) | Avg Volume(3M) | 0.26M | Price | $91 |
| IPO | 2021/4/15 | Option/Short | Yes/Yes | Trades | 4407 | Volume | 231,760 | Change | 0.39% |
A U.S. healthcare company that provides a value-based care platform for primary care physicians. It partners with primary care physician groups to help them transition to risk-bearing, managed care, integrating patient treatment with medical cost management. The company has established itself as a value-based care platform provider focused on primary care.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
Next earnings report: November 4
7 days to go.
AGL has a sound balance sheet but weak earning power
Of every $100 in sales, $4.29 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +90.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $26. Peers typically go for $89.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 72.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 48 in the industry
Based on market cap of $2B.
FAQ
What kind of company is AGL?
AGL belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of AGL?
The market cap of AGL is approximately $1.5B, ranking 2,292 within its sector.
What is the 52-week high and low for AGL?
AGL has recorded a 52-week high of $133.04 and a low of $7.48.
